Session » Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

Date: Sunday, November 13, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 1564

Anti-TNF versus Anti-IL6 Receptor Antagonist Therapy in Severe Ocular Involvement in Behçet’s Disease

1:00PM-3:00PM: Abstract Number: 1572

CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis

1:00PM-3:00PM: Abstract Number: 1575

Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis

1:00PM-3:00PM: Abstract Number: 1576

Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis

1:00PM-3:00PM: Abstract Number: 1563

Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Incomplete Behçet’s Disease

1:00PM-3:00PM: Abstract Number: 1555

Comparison Between Clinical Features, Acute Phase Reactants, Imaging Between Takayasu and LV-GCA Patients at Diagnosis and During Follow-up in Italian Patients in Monocentric Study

1:00PM-3:00PM: Abstract Number: 1571

Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort

1:00PM-3:00PM: Abstract Number: 1561

Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

1:00PM-3:00PM: Abstract Number: 1565

Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease

1:00PM-3:00PM: Abstract Number: 1556

Distinct Clinical and Therapeutic Features Between Parenchymal and Non-parenchymal Manifestations in Neurobehçet’s Disease

1:00PM-3:00PM: Abstract Number: 1553

Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1547

Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica

1:00PM-3:00PM: Abstract Number: 1568

Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and Eligibility in a Prospective Cohort of Patients with VEXAS

1:00PM-3:00PM: Abstract Number: 1548

Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients

1:00PM-3:00PM: Abstract Number: 1577

Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life

1:00PM-3:00PM: Abstract Number: 1545

Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica

1:00PM-3:00PM: Abstract Number: 1550

Involvement of Iliofemoral Arteries in PET/CT Are Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

1:00PM-3:00PM: Abstract Number: 1544

Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica

1:00PM-3:00PM: Abstract Number: 1559

Long Term Clinical Effects of Apremilast on Behcet’s Disease and Changes in Serum Cytokines

1:00PM-3:00PM: Abstract Number: 1578

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

1:00PM-3:00PM: Abstract Number: 1569

Lung Involvement in VEXAS Syndrome

1:00PM-3:00PM: Abstract Number: 1570

Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning

1:00PM-3:00PM: Abstract Number: 1557

Microvascular Involvement in Behçet’s Disease: Study of Nailfold Capillaroscopy in Patients from a National Referral Center

1:00PM-3:00PM: Abstract Number: 1560

Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease

1:00PM-3:00PM: Abstract Number: 1566

Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study

1:00PM-3:00PM: Abstract Number: 1558

Prevalence, Phenotypical Clinical Clusters and Treatment of Neurobehçet’s Disease: Study in Northern Spain

1:00PM-3:00PM: Abstract Number: 1552

Rare Variant Analysis of Aortopathy Genes in Takayasu’s Arteritis

1:00PM-3:00PM: Abstract Number: 1567

Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol

1:00PM-3:00PM: Abstract Number: 1543

Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR

1:00PM-3:00PM: Abstract Number: 1554

Serum Biomarkers in Association with Clinical and Vascular Disease Activity in Takayasu’s Arteritis

1:00PM-3:00PM: Abstract Number: 1551

The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis

1:00PM-3:00PM: Abstract Number: 1549

Toward Safer Glucocorticoid Therapy

1:00PM-3:00PM: Abstract Number: 1546

Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry

1:00PM-3:00PM: Abstract Number: 1562

Validation of Behçet’s Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

1:00PM-3:00PM: Abstract Number: 1574

Vasculitides as Medication-Associated Adverse Events Based on a National Database Reporting System

1:00PM-3:00PM: Abstract Number: 1573

Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].